Related references
Note: Only part of the references are listed.Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Jonathan I. Epstein et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
J-L Lee et al.
BRITISH JOURNAL OF CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2014)
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Oriana Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 ( Alliance)
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
Mark Thalgott et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial
Andrea Guttilla et al.
RADIATION ONCOLOGY (2014)
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2013)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran et al.
EUROPEAN UROLOGY (2013)
Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
Karim S. Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
David I. Quinn et al.
LANCET ONCOLOGY (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C. Araujo et al.
LANCET ONCOLOGY (2013)
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Pirkko-Liisa Kellokumpu-Lehtinen et al.
LANCET ONCOLOGY (2013)
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis et al.
LANCET ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate Cancer
Mari Nakabayashi et al.
UROLOGY (2013)
Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
Juan Miguel Mosquera et al.
NEOPLASIA (2013)
Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
Maria Thadani-Mulero et al.
CANCER RESEARCH (2012)
Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
Nicholas Mitsiades et al.
CANCER RESEARCH (2012)
Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group
Glenn Liu et al.
CLINICAL GENITOURINARY CANCER (2012)
Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
A. Bryce et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
Himisha Beltran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives
Nagalakshmi Nadiminty et al.
WORLD JOURNAL OF UROLOGY (2012)
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
A. Flechon et al.
ANNALS OF ONCOLOGY (2011)
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy
Jochen Walz et al.
BJU INTERNATIONAL (2011)
Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castration-Resistant Prostate Cancer After Docetaxel-Based Therapy A Phase 2 Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
Andrea L. Harzstark et al.
CANCER (2011)
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Medha S. Darshan et al.
CANCER RESEARCH (2011)
Targeting Continued Androgen Receptor Signaling in Prostate Cancer
Christophe Massard et al.
CLINICAL CANCER RESEARCH (2011)
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Gerhardt Attard et al.
CLINICAL CANCER RESEARCH (2011)
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
Stephane Oudard
FUTURE ONCOLOGY (2011)
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study
Tanya B. Dorff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
Emma Hornberg et al.
PLOS ONE (2011)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran et al.
CANCER DISCOVERY (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
PHASE III MULTI-INSTITUTIONAL TRIAL OF ADJUVANT CHEMOTHERAPY WITH PACLITAXEL, ESTRAMUSTINE, AND ORAL ETOPOSIDE COMBINED WITH LONG-TERM ANDROGEN SUPPRESSION THERAPY AND RADIOTHERAPY VERSUS LONG-TERM ANDROGEN SUPPRESSION PLUS RADIOTHERAPY ALONE FOR HIGH-RISK PROSTATE CANCER: PRELIMINARY TOXICITY ANALYSIS OF RTOG 99-02
Seth A. Rosenthal et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
Robert W. Ross et al.
CANCER (2008)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Preclinical antitumor activity of the oral platinum analog satraplatin
Katja Wosikowski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2007)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
MD Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemistry and structural biology of androgen receptor
WQ Gao et al.
CHEMICAL REVIEWS (2005)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer
R Dreicer et al.
UROLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma - Cancer and leukemia group B 99813
WK Oh et al.
CANCER (2003)
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer
W Berry et al.
JOURNAL OF UROLOGY (2002)
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
TM Beer et al.
ANNALS OF ONCOLOGY (2001)